Advantage Alpha Capital Partners LP Sells 21,053 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Advantage Alpha Capital Partners LP trimmed its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 45.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,098 shares of the biopharmaceutical company's stock after selling 21,053 shares during the period. Advantage Alpha Capital Partners LP's holdings in Dynavax Technologies were worth $321,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PDT Partners LLC bought a new stake in Dynavax Technologies in the 3rd quarter valued at $3,967,000. Nordea Investment Management AB grew its position in Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock worth $10,034,000 after buying an additional 232,690 shares in the last quarter. Barclays PLC increased its stake in Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after acquiring an additional 175,118 shares during the period. Bank of Montreal Can raised its holdings in Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock valued at $11,848,000 after acquiring an additional 82,449 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Dynavax Technologies in the 4th quarter worth approximately $990,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX traded down $0.04 on Friday, hitting $13.68. The stock had a trading volume of 1,368,915 shares, compared to its average volume of 2,136,230. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of 76.00 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm's 50 day moving average price is $13.35 and its 200-day moving average price is $12.49. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. On average, equities research analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on DVAX. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price objective for the company from $15.00 to $12.00 in a report on Tuesday, February 11th.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.